An announcement from Biora Therapeutics (BIOR) is now available.
Biora Therapeutics, Inc. has announced encouraging preliminary results from its BT-600 clinical trial, indicating effective delivery and absorption of the drug for ulcerative colitis treatment with their innovative NaviCap device. The trial showed a desirable pharmacokinetic profile, suggesting that the device can deliver medication directly to the colon, thus reducing systemic drug exposure. These findings, alongside the good tolerance observed in trial participants, mark a significant step forward in the therapy’s development. Further details will be discussed in an upcoming conference call, with additional information available on the company’s website.
For detailed information about BIOR stock, go to TipRanks’ Stock Analysis page.
